Digital Therapeutics are patient 必威手机APPhealth applications and connected devices that have proven clinical benefits, as well as, appropriate regulatory clearances and distribution pathways to serve their intended use. Recent reporting by the IQVIA Institute has identified a large, growing number of such apps with the potential to save billions in unnecessary healthcare costs.1 This value drives strong industry growth projections, with some forecasting that Digital Therapeutics sales will expand to $USD 9.4 billion worldwide by 2025.2
在许多方面，英国有能力成长并赶上数字治疗行业的市场领导者。迄今为止，只有8％的已发表的应用程序有效性研究已在英国进行。32017年，全球数字健康初创公司投资了142亿美元，但仅在英国数字健康健康中投资了4.26亿美元（3％）必威手机APP启动4
英国在数字健康方面的全球地位必威手机APP
If Digital Therapeutics companies could conduct their studies better, faster, and cheaper in the UK than elsewhere, the benefits to the 必威手机APPhealth and wealth of the nation would be significant. Improving the UK’s Digital Therapeutics research infrastructure would position the nation for more investment in research and downstream commercial activity; UK startups would become more competitive, and more world leaders in Digital Therapeutics would want to set up operations in the UK. However, to realise these clinical and economic benefits, the leading apps that drive this value would likely need to be studied in NHS patients prior to their broad adoption.
The research needs of the Digital Therapeutics industry are – at the highest level – fairly uniform and well understood. To be sustainably successful, Digital Therapeutics developers of all kinds need an efficient means of proving their effectiveness, safety and cost-effectiveness relative to the standard of care in a setting that very closely resembles real world practice. In fact, most industry participants would agree that the main problem with current infrastructure is not necessarily ‘quality;’ it’s the excessive time and cost of today’s studies together with the struggle to transition seamlessly from research to real world practice.
数字治疗研究的交钥匙解决方案
英国有机会提供世界上第一个用于数字治疗研究的交钥匙解决方案。这种解决方案的关键特征应包括以下内容：
Simplified application & setup
The commonalities of many Digital Therapeutics create the opportunity for a ‘templated’ approach to developing study protocols, drafting ethics review applications, and matching promising studies to potential funding sources.
Pre-contracted ‘Digital Therapeutics Research Network’
数字治疗公司通常需要数年时间才能与合适的研究站点找到并建立适当的法律协议。立即“插入”适当网站网络的能力对于该行业来说是无价的。
App prescribing platform & 3rd party research apps
研究应最大程度地减少临床医生和患者所需的工作。可以通过为患者提供对研究术语的能力，并为合格的研究人员提供单一的Colleated EMR，APP和其他必威手机APP数据来分析的能力，从而实现重要效率，从而可以实现高度效率。。
合格的独立研究团队的“长凳”
应使用具有专业知识的学术和私营部门团队的列表，该团队应在化下的数据管理和分析方面进行专业知识，以准备符合高质量出版标准的手稿，例如WHO的“ MERA”清单。5
Ability to transition intermediately to use in ‘monitored’ routine care
While research can be improved, perhaps an even larger issue for Digital Therapeutics companies is the need to achieve scale. It would make sense to use a common infrastructure for research and routine care to enable seamless transitions.
交钥匙数字治疗平台
使上述现实所需的“投资”不在新技术中，因为该技术已经存在。成为数字治疗学领域的世界领导者所需的投资是在公众，学术和工业领域的合作。需要在新的过程中达成共识，以使英国的数字治疗行业具有常识。
参考
1伊克维亚研究所。英国数字健康的不断增长。必威手机APP2017年11月7日。
2Grand View Research.Digital Therapeutics Market by Application.2017年7月。
3IQVIA AppScript Clinical Evidence Database.文件上的数据。13 March, 2018.
4Marc Sluijs. Digital必威手机APPHealth.Network Deals Database. 15 March 2018.
5S. Agarwal. Guidelines for reporting of 必威手机APPhealth interventions using mobile phones: mobile health (mHealth) evidence reporting and assessment (mERA) checklist. BMJ 2016;352:i1174. 17 March 2016